Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the first quarter ended March 31, 2024.
圣地亚哥，2024年5月8日（GLOBE NEWSWIRE）——Belite Bio, Inc（纳斯达克股票代码：BLTE）是一家临床阶段的生物制药药物开发公司，专注于推进针对医疗需求严重未得到满足的退行性视网膜疾病的新疗法。该公司今天宣布，将于美国东部时间2024年5月14日星期二下午 4:30 举办网络直播，讨论该公司的财务业绩，并提供截至2024年3月31日的第一季度业务最新情况。
Webcast Information
Date: Tuesday, May 14, 2024
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link:
网络直播信息
日期：2024 年 5 月 14 日星期二
时间：美国东部时间下午 4:30（太平洋时间下午 1:30）
网络直播链接：
Webcast Link Instructions
You can join the live webcast by visiting the link above or the "Presentations & Events" section of the Company's Investor Relations website at A replay will be available for approximately 90 days after the event.
网络直播链接说明
您可以通过访问上面的链接或公司投资者关系网站的 “演示与活动” 部分来参加网络直播。活动结束后约90天内将提供重播。
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs such as (i) atrophic age-related macular degeneration (AMD), commonly known as Geographic Atrophy (GA) in advanced dry AMD, and (ii) autosomal recessive Stargardt disease type 1, or STGD1, in addition to specific metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at .
关于 Belite Bio
Belite Bio是一家临床阶段的生物制药药物开发公司，专注于推进针对视网膜退行性眼病的新疗法，这些疾病的医疗需求尚未得到满足，例如（i）萎缩性年龄相关性黄斑变性（AMD），在晚期干性 AMD 中通常称为地理萎缩 (GA)，以及 (ii) 常染色体隐性遗传型 1 型斯塔加特病或 STGD1，以及特定的代谢性疾病。欲了解更多信息，请在推特、Instagram、领英、脸书上关注我们或访问我们。
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
媒体和投资者关系联系人：
吴珍妮
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
朱莉·法伦
belite@argotpartners.com
译文内容由第三方软件翻译。